Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy.
Melody M, Epperla N, Shouse G, Romancik J, Allen P, Moyo TK, Kenkre V, Ollila T, Fitzgerald L, Hess B, David K, Herr MM, Odetola O, Lin A, Moreira J, Ma S, Winter JN, Roy I, Stephens D, Danilov A, Shah NN, Barta SK, Cortese M, Cohen JB, Gordon LI, Karmali R. Melody M, et al. Among authors: winter jn. Blood Adv. 2024 May 28;8(10):2327-2331. doi: 10.1182/bloodadvances.2024012573. Blood Adv. 2024. PMID: 38498727 Free PMC article. No abstract available.
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.
Wallace DS, Rowland C, Hill BT, Baran AM, Casulo C, Reagan PM, Winter A, Karmali R, Winter JN, Gordon LI, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Ma S, Barr PM. Wallace DS, et al. Among authors: winter jn. Leuk Lymphoma. 2023 Sep;64(9):1579-1582. doi: 10.1080/10428194.2023.2223743. Epub 2023 Jun 21. Leuk Lymphoma. 2023. PMID: 37341984 Clinical Trial. No abstract available.
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
Hill BT, Ma S, Zent CS, Baran AM, Wallace DS, Advani A, Winter A, Winter J, Gordan L, Karmali R, Liesveld JL, Mulford DA, Rowland C, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Barr PM. Hill BT, et al. Blood Adv. 2024 Jan 23;8(2):378-387. doi: 10.1182/bloodadvances.2023010693. Blood Adv. 2024. PMID: 37871300 Free PMC article.
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy.
Karmali R, Machhi R, Epperla N, Shouse G, Romancik J, Moyo TK, Kenkre V, Ollila TA, Fitzgerald L, Hess B, David K, Roy I, Zurko J, Chowdhury SM, Annunzio K, Ferdman R, Bhansali RS, Harris EI, Liu J, Nizamuddin I, Ma S, Moreira J, Winter J, Pro B, Stephens DM, Danilov A, Shah NN, Cohen JB, Barta SK, Torka P, Gordon LI. Karmali R, et al. Blood Adv. 2024 May 28;8(10):2592-2599. doi: 10.1182/bloodadvances.2023011996. Blood Adv. 2024. PMID: 38531057
Predicting outcomes in CNS lymphoma with ctDNA.
Winter JN, Ferreri AJM. Winter JN, et al. Blood. 2024 Feb 8;143(6):478-480. doi: 10.1182/blood.2023023008. Blood. 2024. PMID: 38329774 No abstract available.
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, Lee CJ, Ollila T, Shouse G, Danilov AV, David KA, Torka P, Hashmi H, Hess B, Barta SK, Romancik JT, Cohen JB, Annunzio K, Kittai AS, Reneau J, Zurko J, Nizamuddin IA, Winter JN, Gordon LI, Ma S, Patel R, Nastoupil L, Ahmed S, Karmali R. Epperla N, et al. Among authors: winter jn. J Hematol Oncol. 2023 Nov 9;16(1):111. doi: 10.1186/s13045-023-01508-3. J Hematol Oncol. 2023. PMID: 37946255 Free PMC article.
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.
Karmali R, Abramson JS, Stephens DM, Barnes J, Winter JN, Ma S, Gao J, Kaplan J, Petrich AM, Hochberg E, Takvorian T, Mi X, Nelson V, Gordon LI, Pro B. Karmali R, et al. Among authors: winter jn. Blood Adv. 2023 Dec 12;7(23):7361-7368. doi: 10.1182/bloodadvances.2023011271. Blood Adv. 2023. PMID: 37756532 Free PMC article.
Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL.
Xu-Monette ZY, Li Y, Snyder T, Yu T, Lu T, Tzankov A, Visco C, Bhagat G, Qian W, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Wang Y, Go H, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Fan X, van Krieken JH, Piris MA, Winter JN, Au Q, Kirsch I, Zhang M, Shaughnessy J, Xu B, Young KH. Xu-Monette ZY, et al. Among authors: winter jn. Clin Cancer Res. 2023 Dec 1;29(23):4808-4821. doi: 10.1158/1078-0432.CCR-23-1554. Clin Cancer Res. 2023. PMID: 37728879 Free PMC article.
194 results